Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients

Clinical trial data of BNT162b2 vaccine estimated an early vaccine efficacy in preventing COVID-19 of 52·4% before dose two, and 90.5% on days 2–7 after dose two.2 A recent analysis of BNT162b2 vaccine data estimated vaccine efficacy of 89–91% during days 15–28 after the first dose.3 We examined ear...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet (British edition) 2021-03, Vol.397 (10277), p.875-877
Hauptverfasser:	Amit, Sharon, Regev-Yochay, Gili, Afek, Arnon, Kreiss, Yitshak, Leshem, Eyal
Format:	Artikel
Sprache:	eng
Schlagworte:	Asymptomatic Asymptomatic infection Coronaviruses Correspondence COVID-19 COVID-19 - epidemiology COVID-19 - prevention & control COVID-19 - transmission COVID-19 vaccines COVID-19 Vaccines - therapeutic use Dosage Health care facilities Humans Immunization Infections Infectious Disease Transmission, Patient-to-Professional - prevention & control Israel - epidemiology Mass Vaccination Medical Staff, Hospital Pandemics - prevention & control Questionnaires Retrospective Studies SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Surveillance Vaccine efficacy Vaccines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Clinical trial data of BNT162b2 vaccine estimated an early vaccine efficacy in preventing COVID-19 of 52·4% before dose two, and 90.5% on days 2–7 after dose two.2 A recent analysis of BNT162b2 vaccine data estimated vaccine efficacy of 89–91% during days 15–28 after the first dose.3 We examined early reductions in SARS-CoV-2 infection and COVID-19 rates in vaccinated HCWs. Active daily symptom reporting and immediate same-day testing allowed for prompt (
ISSN:	0140-6736 1474-547X
DOI:	10.1016/S0140-6736(21)00448-7